pharma · Breast Cancer · Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
Pierre Fabre Medicament
PIERRE FABRE MEDICAMENT is a pharma organization headquartered in LAVAUR, FR. Primary therapeutic focus areas include Breast Cancer, Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease, X-linked hyp
LAVAUR, FR HQ
176 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- LAVAUR, FR
- Employees
- 176
- Programs
- 8
- Drugs
- 13
- Patents
- 0
KN-8701/KIN2787CI101
Phase 1 · other · Participants with BRAF and/or NRAS mutation positive tumors
KN-8701/KIN2787CI101 for Participants with BRAF and/or NRAS mutation positive tumors is a Phase 1 program (other) at Pierre Fabre Medicament with 1 ClinicalTrials.gov record(s).
Internal code KN-8701/KIN2787CI101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pierre Fabre Medicament
- Phase
- Phase 1
- Modality
- other
- Indication
- Participants with BRAF and/or NRAS mutation positive tumors
- Status
- active
- Trials
- 1